PROGRAF Hard Capsules, Tacrolimus, Prograf 0.5 mg hard capsule, Medicine and Disease informationBy viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use. Prograf 0.5 mg hard capsules - Capsule, hard, Opaque light yellow hard gelatin capsules imprinted in red with "0.5 mg" and "[f] 607", containing white powder. Prograf 1 mg hard capsules - Capsule, hard, Opaque white hard gelatin capsules imprinted in red with "1 mg" and "[f] 617", containing white powder. Prograf 5 mg hard capsules - Capsule, hard, Opaque greyish red hard gelatin capsules imprinted in white with "5 mg" and "[f] 657", containing white powder. Prograf therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients. General considerations The recommended initial dosages presented below are intended to act solely as a guideline. Prograf dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see below for recommended target whole blood trough concentrations). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered. Prograf can be administered intravenously or orally. In general, dosing may commence orally; if necessary, by administering the capsule contents suspended in water, via nasogastric tubing. Prograf is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period. The Prograf dose may vary depending upon the immunosuppressive regimen chosen. Method of administration It is recommended that the oral daily dose be administered in two divided doses (e.g. morning and evening).